Ravulizumab and COVID-19
NCT04570397
·
clinicaltrials.gov ↗
PHASE3
Phase
UNKNOWN
Status
32
Enrollment
OTHER
Sponsor class
Conditions
Covid19
Thrombotic Microangiopathies
Acute Kidney Injury
Interventions
DRUG:
Ravulizumab
Sponsor
Brigham and Women's Hospital